BC Platforms (BCP), a global leader in health care data management and analytics, today announced a partnership with analytics leader SAS to support customers in health care and life sciences.
SAS’ powerful analytics for health care and life sciences, combined with the repeatable, modular and ease-of-use data management capabilities of BC Platforms, will provide swift and controlled access to expertly curated patient data.
The partnership formed as both companies have several key clients in common, including global pharmaceutical companies and health care provider organizations. BC Platforms and SAS will discover new ways to derive insights from genomics and other patient data, such as imaging and blood chemistry, using state-of-the-art software. The partnership helps companies overcome limitations from data held in silos, simplifies the normalization of complex nonlinear data sets and democratizes access to analytics tools that better predict health outcomes.
Major pharmaceutical companies use SAS’ sophisticated analytics toolbox when submitting regulatory dossiers to global regulatory authorities. Similarly, pharmaceutical companies use BCP’s data management platform BC|INSIGHT and global real-world data (RWD) access network to normalize, curate and harmonize all in-house data assets and seamlessly connect them with net new RWD assets to accelerate R&D and commercialization efforts.
Nino da Silva, Deputy Managing Director at BCP, said, “We are delighted to work with SAS, one of the world’s greatest names in software analytics. Big data is not close to reaching its full potential in health. But through our partnership, which provides access to carefully curated patient data, including genomic data, we will deliver tangible results that will make a difference to drug development, health care provision and patient outcomes. We’re better together, narrowing the gap for our customers between multiple data type integrations to support better, faster and more cost-effective clinical decision making.”
Scott McClain, Principal Industry Consultant at SAS, commented, “Today, the lightning pace of the digital revolution in medical life science means customers make critical, data-driven decisions with rapid speed. SAS and BC Platforms’ combined power in data management and analytics ensures users get closer to the high-quality genomics and real-world data networks they need to make bold discoveries that drive progress.”
In 2020, the top 15 highest-revenue life sciences companies spent more than $120 billion on R&D programs. Clinical programs are a significant part of that spending and more than 60% of new clinical trials started in highly segmented patient populations. BCP’s Data Access Platform is fundamental to securing more diverse patient data across many therapeutic areas, including cancer, cardiovascular and rare diseases. The collaboration will also support studies of natural disease progression and target identification, plus ensure that clinical trials have quality sourced data for external control arms.
To meet BCP and SAS, visit Booth 808 at the Bio-IT World Precision Medicine Conference at the Hynes Convention Center in Boston, May 3-5. Learn more at bio-itworldexpo.com/22.